<?xml version="1.0" encoding="UTF-8"?>
<p id="par0075">CP means of antibody transfer to provide passive immunity. The history of CP therapy is based on the 1890s used to protect against bacterial toxins [
 <xref rid="bib0045" ref-type="bibr">9</xref>]. Intravenous immunoglobulins collected from thousands of healthy donors are still used today to prevent viral infections in some patient populations. CP transfusion has been reported in the treatment of various infections over the past decades [
 <xref rid="bib0050" ref-type="bibr">10</xref>]. In the past two decades, CP therapy has been used with satisfactory efficacy and safety in the treatment of SARS-CoV-1, MERS-CoV and 2009 H1N1 outbreak [
 <xref rid="bib0055" ref-type="bibr">11</xref>,
 <xref rid="bib0060" ref-type="bibr">12</xref>]. Therefore, the use of passive antibody transfer is considered for treating Covid-19 patients. The FDA has approved the use of experimental CP therapy in clinical trials and critical Covid-19 patients without other treatment options, and has published a guideline for this purpose [
 <xref rid="bib0065" ref-type="bibr">13</xref>]. In order for CP treatment to be effective, it is a prerequisite to find suitable donors with a high level of neutralizing antibodies [
 <xref rid="bib0055" ref-type="bibr">11</xref>].
</p>
